Product Description
Cetylpyridinium chloride, (CPC, CAS 123-03-5) as active ingredient of antiseptic oral mouthrinses has a broad antimicrobial spectrum with a rapid bactericidal effect on gram-positive pathogens and a fungicide effect on yeasts in particular. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11505791/)
Mechanisms of Action: Cell Membrane Damager
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Hong Kong | Hungary | India | Ireland | Italy | Korea | Malaysia | Malta | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | Serbia | Slovenia | South Africa | Spain | Taiwan | Turkey | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Aziende Chimiche Riunite Angelini Francesco S.p.A
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CRO-2022-04-FLU-REG-BZ-ZM | P3 |
Completed |
Influenza, Human |
2022-10-06 |